ARTICLE | Company News
Janssen submits simeprevir NDA
March 29, 2013 12:12 AM UTC
The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) submitted an NDA to FDA for simeprevir ( TMC435) to treat HCV genotype 1 infection. The submission triggers a EUR 10 million...